Abstract
To relate the clinical findings of parvovirus B19 infection to the phase of the disease, we performed a retrospective chart review of 30 adult patients who tested positive for IgM antibody against parvovirus B19 at our hospital from March 2003 to November 2008. Median patient age was 38 years, with 86.7% aged between 26 and 45 years. The male-to-female ratio was 4:26 (86.7% female). Symptoms in the first phase were mainly flu-like, including fever, headache, or myalgia. Symptoms in the second phase were arthralgia in 24 (85.7%) and rash in 23 (82.1%). Fever was observed in 21 (70.0%), and 22 (75.9%) were found to be lymphopenic. The onsets in 73.3% of cases were concentrated within 10.1% of the study period, an observation nearly consistent with an outbreak of erythema infectiosum. Three patients had symmetrical swelling of joints, all of whom also had rash. Most patients visited the hospital within a week of onset and prognosis was favorable. In the parvovirus B19 infection, flu-like symptoms were frequent in the first phase, while rash and arthralgia were common in the second. Female sex, age between 26 and 45, and presence of rash, arthralgia, fever, and lymphopenia were clinical findings with a high frequency (≥70%), and these factors may contribute to diagnosis. In an era when early diagnosis and therapy is required in rheumatoid arthritis, it is important to recognize the parvovirus B19 infection with a presentation of acute arthritis and a favorable prognosis.
Similar content being viewed by others
References
Young NS, Brown KE. Parvovirus B19. N Engl J Med. 2004;350:586–97.
Woolf AD, Campion GV, Chishick A, Wise S, Cohen BJ, et al. Clinical manifestations of human parvovirus B19 in adults. Arch Intern Med. 1989;149:1153–6.
Hayakawa H, Tara M, Niina K, Osame M. A clinical study of adult human parvovirus B19 infection. Intern Med. 2002;41:295–9.
Scroggie DA, Carpenter MT, Cooper RI, Higgs JB. Parvovirus arthropathy outbreak in southwestern United States. J Rheumatol. 2000;27:2444–8.
White DG, Woolf AD, Mortimer PP, Cohen BJ, Blake DR, et al. Human parvovirus arthropathy. Lancet. 1985;1:419–21.
Bell LM, Naides SJ, Stoffman P, Hodinka RL, Plotkin SA. Human parvovirus B19 infection among hospital staff members after contact with infected patients. N Engl J Med. 1989;321:485–91.
Reid DM, Reid TM, Brown T, Rennie JA, Eastmond CJ. Human parvovirus-associated arthritis: a clinical and laboratory description. Lancet. 1985;1:422–5.
Anderson MJ, Higgins PG, Davis LR, Willman JS, Jones SE, et al. Experimental parvoviral infection in humans. J Infect Dis. 1985;152:257–65.
Anderson LJ. Role of parvovirus B19 in human disease. Pediatr Infect Dis J. 1987;6:711–8.
Epidemiology Information Bureau of Kyoto City Health & Welfare Department (2010) Webpage. http://www.city.kyoto.lg.jp/hokenfukushi/page/0000009961.html. Accessed 3 May 2010.
Naides SJ, Field EH. Transient rheumatoid factor positivity in acute human parvovirus B19 infection. Arch Intern Med. 1988;148:2587–9.
Acknowledgments
The authors thank Mr. Kenichi Miyake, Kyoto City Institute of Health and Environmental Sciences, and Dr. Nobuhiko Okabe, National Institute of Infectious Diseases, for their kind advice on sentinel surveillance in erythema infectiosum.
Conflict of interest
None.
Author information
Authors and Affiliations
Corresponding author
About this article
Cite this article
Oiwa, H., Shimada, T., Hashimoto, M. et al. Clinical findings in parvovirus B19 infection in 30 adult patients in Kyoto. Mod Rheumatol 21, 24–31 (2011). https://doi.org/10.1007/s10165-010-0338-y
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10165-010-0338-y